Medicines' single-dose ABSSSI drug Orbactiv OK'd
This article was originally published in Scrip
Executive Summary
The FDA on 6 August granted approval to The Medicines' Company's Orbactiv (oritavancin) as a treatment for acute bacterial skin and skin structure infections (ABSSSI) – making it the third new antibiotic to win the agency's blessing for that indication in the past few months.